{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:08:33Z","timestamp":1788732513846,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,6]]},"DOI":"10.7759\/cureus.115865","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:00:12Z","timestamp":1788732012000},"source":"Crossref","is-referenced-by-count":0,"title":["A Registry-Based Perspective of Interventional Clinical Trials for Duchenne Muscular Dystrophy"],"prefix":"10.7759","author":[{"given":"Jeet H","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiya O","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswabhaskar","family":"Susarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Subramanya","family":"Kashyap Peraboina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrabya","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery AE","year":"2002","unstructured":"Emery AE. The muscular dystrophies. Lancet. 2002, 359:687-95. 10.1016\/S0140-6736(02)07815-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant DJ","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018, 17:251-67. 10.1016\/S1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan D","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021, 7:13. 10.1038\/s41572-021-00248-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant DJ","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018, 17:347-61. 10.1016\/S1474-4422(18)30025-5","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210682","article-title":"Exon-skipping in Duchenne muscular dystrophy","volume":"8","author":"Takeda S","year":"2021","unstructured":"Takeda S, Clemens PR, Hoffman EP. Exon-skipping in Duchenne muscular dystrophy. J Neuromuscul Dis. 2021, 8:S343-58. 10.3233\/JND-210682","journal-title":"J Neuromuscul Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00486-7","article-title":"Value: Restoring protein expression in neuromuscular conditions: a review assessing the current state of exon skipping\/inclusion and gene therapies for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"35","author":"Sheikh O","year":"2021","unstructured":"Sheikh O, Yokota T. Value: Restoring protein expression in neuromuscular conditions: a review assessing the current state of exon skipping\/inclusion and gene therapies for Duchenne muscular dystrophy and spinal muscular atrophy. BioDrugs. 2021, 35:389-99. 10.1007\/s40259-021-00486-7","journal-title":"BioDrugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant DJ","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018, 17:445-55. 10.1016\/S1474-4422(18)30026-7","journal-title":"Lancet Neurol"},{"key":"ref8","unstructured":"ClinicalTrials.gov. U.S. National Library of Medicine. (2026). Accessed. May 29, 2026: https:\/\/clinicaltrials.gov\/."},{"key":"ref9","unstructured":"U.S. Department of Health and Human Services, Office for Human Research Protections. 45 CFR 46. (2026). Accessed: September 5, 2026: https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/index.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030830","article-title":"A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies","volume":"11","author":"Heydemann A","year":"2023","unstructured":"Heydemann A, Siemionow M. A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies. Biomedicines. 2023, 11:23-5. 10.3390\/biomedicines11030830","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2025.104397","article-title":"Duchenne muscular dystrophy: evolving therapeutic strategies and multidimensional evaluation approaches","volume":"47","author":"Komaki H","year":"2025","unstructured":"Komaki H. Duchenne muscular dystrophy: evolving therapeutic strategies and multidimensional evaluation approaches. Brain Dev. 2025, 47:104397. 10.1016\/j.braindev.2025.104397","journal-title":"Brain Dev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1183101","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","volume":"14","author":"Bez Batti Angulski A","year":"2023","unstructured":"Bez Batti Angulski A, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J, Metzger JM. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023, 14:1183101. 10.3389\/fphys.2023.1183101","journal-title":"Front Physiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2150543","article-title":"Biological and genetic therapies for the treatment of Duchenne muscular dystrophy","volume":"23","author":"Wilton-Clark H","year":"2023","unstructured":"Wilton-Clark H, Yokota T. Biological and genetic therapies for the treatment of Duchenne muscular dystrophy. Expert Opin Biol Ther. 2023, 23:49-59. 10.1080\/14712598.2022.2150543","journal-title":"Expert Opin Biol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart IE","year":"2019","unstructured":"Verhaart IE, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019, 15:373-86. 10.1038\/s41582-019-0203-3","journal-title":"Nat Rev Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2313105","article-title":"Duchenne muscular dystrophy: promising early-stage clinical trials to watch","volume":"33","author":"Tang A","year":"2024","unstructured":"Tang A, Yokota T. Duchenne muscular dystrophy: promising early-stage clinical trials to watch. Expert Opin Investig Drugs. 2024, 33:201-17. 10.1080\/13543784.2024.2313105","journal-title":"Expert Opin Investig Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0408-z","article-title":"Improving clinical trial design for Duchenne muscular dystrophy","volume":"15","author":"Merlini L","year":"2015","unstructured":"Merlini L, Sabatelli P. Improving clinical trial design for Duchenne muscular dystrophy. BMC Neurol. 2015, 15:153. 10.1186\/s12883-015-0408-z","journal-title":"BMC Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000243","article-title":"Duchenne muscular dystrophy: clinical trials and emerging tribulations","volume":"28","author":"Shieh PB","year":"2015","unstructured":"Shieh PB. Duchenne muscular dystrophy: clinical trials and emerging tribulations. Curr Opin Neurol. 2015, 28:542-6. 10.1097\/WCO.0000000000000243","journal-title":"Curr Opin Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1055\/a-2648-3203","article-title":"Inequitable racial and ethnic representation in Duchenne muscular dystrophy clinical trials","volume":"56","author":"Creasey M","year":"2025","unstructured":"Creasey M, Thangarajh M. Inequitable racial and ethnic representation in Duchenne muscular dystrophy clinical trials. Neuropediatrics. 2025, 56:397-400. 10.1055\/a-2648-3203","journal-title":"Neuropediatrics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.04.001","article-title":"Engaging participants in rare disease research: a qualitative study of Duchenne muscular dystrophy","volume":"38","author":"Bendixen RM","year":"2016","unstructured":"Bendixen RM, Morgenroth LP, Clinard KL. Engaging participants in rare disease research: a qualitative study of Duchenne muscular dystrophy. Clin Ther. 2016, 38:1474-84. 10.1016\/j.clinthera.2016.04.001","journal-title":"Clin Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/520523-a-registry-based-perspective-of-interventional-clinical-trials-for-duchenne-muscular-dystrophy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:00:14Z","timestamp":1788732014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/520523-a-registry-based-perspective-of-interventional-clinical-trials-for-duchenne-muscular-dystrophy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.115865","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}